

**Extraordinary Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
7 December 2021
Virtual meeting
Agenda**

Tuesday, 7 December 2021

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
11:00	Opening and welcome Opening: DDG Welcome: A. CRAVIOTO. SAGE Chair. 5 min.	Opening of the plenary meeting	5 min.
11:05	Introduction and objective setting Introduction to the session in the global context of vaccine supply and the new variant of concern (Omicron). K. O'BRIEN. Director Immunization Vaccines and Biologicals (IVB). 10 min. Objective setting. H. NOHYNEK. SAGE Working Group Chair. 5 min.	FOR INFORMATION	15 min.
11:20	J&J Update of recommendations Presentation of clinical trials data. P. SMITH. 10 min. Presentation of vaccine effectiveness data. D. FEIKIN/ M. PATEL. IVB. 10 min. Recommendations. A. WILDER-SMITH. IVB. 10 min. Discussion and conclusions. 30 min.	FOR RECOMMENDATION	60 min.
12:20	Heterologous schedules Evidence review for heterologous schedules. E. PARKER. IVB. 20 min. Draft recommendations, discussions and conclusions. F. OLAYINKA. SAGE Working Group Co-Chair. 30 min.	FOR RECOMMENDATION	50 min.
13:10	Break	Break	25 min.
13:35	Evidence and considerations for booster vaccination Introduction and objective setting. H. NOHYNEK. SAGE Working Group Chair. 5 min. Vaccine supply forecasts (booster scenarios). T. CERNUSCHI. IVB. 5 min.	FOR INFORMATION	10 min.

13:45	Evidence assessment of effectiveness over time	FOR INFORMATION	50 min.
	Evidence assessment of vaccine effectiveness over time (by subpopulations, clinical endpoints, and against variants) and risk of bias. D. FEIKIN. IVB. 20 min. Questions. 30 min.		
14:35	Immunogenicity, vaccine effectiveness and safety of booster doses	FOR INFORMATION	40 min.
	Immunogenicity, vaccine effectiveness and impact of boosters. D. KASLOW. SAGE Working Group/ M. PATEL. IVB. 20 min. Safety of booster vaccination. S. KOCHHAR. SAGE member. 5 min. Questions. 15 min.		
15:15	Impact modelling	FOR INFORMATION	30 min.
	Impact modelling of booster doses. S. PALLAS/ N. GRASSLY. SAGE Working Group. 15 min. Questions. 15 min.		
15:45	Discussion on the evidence presented on booster vaccination and way forward	FOR INFORMATION AND DISCUSSION	30 min.
	Discussion. H. NOHYNEK. SAGE Working Group Chair Revision of the prioritization roadmap. D. KASLOW. SAGE Working Group		
16:15	Concluding remarks	FOR INFORMATION	5 min.
	Concluding remarks and review of next steps for vaccine-specific interim recommendations. H. NOHYNEK and A. CRAVIOTO. SAGE Working Group Chair and Chair of SAGE. 5 min.		
16:20	End of the meeting		